BIO-key International (NASDAQ:BKYI) Announces Earnings Results, Misses Expectations By $3.66 EPS

BIO-key International (NASDAQ:BKYI) issued its quarterly earnings results on Friday. The technology company reported ($4.01) EPS for the quarter, missing the consensus estimate of ($0.35) by ($3.66), Zacks reports. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $2.40 million. BIO-key International had a negative return on equity of 67.31% and a negative net margin of 50.01%.

Here are the key takeaways from BIO-key International’s conference call:

• Software growth lifted margins: Q3 license-fee revenue rose 39% year over year and reached 86% of total revenue, helping gross margin improve to 90% from 77% and reducing the operating loss 8%. Total revenue nevertheless fell 4%, largely because hardware sales declined.
• International regulated-sector wins expanded the pipeline: BIO-key highlighted new government and financial-services customers, including the Central Bank of Jordan, and said it has added eight Middle East customers in roughly seven months. Management described larger opportunities ahead, but timing and collections remain dependent on customer and partner deployments.
• New U.S. opportunities and product initiatives: A casino resort signed a prepaid, three-year PortalGuard agreement, and BIO-key said its FIDO-certified Passkey:YOU product is nearing launch, with agentic-AI authentication as a potential use case. Management sees partner-led sales and additional verticals as growth opportunities, though adoption is not yet established.
• Balance sheet strengthened: The company retired its remaining note debt, ended the quarter with $2.2 million in cash and $3.1 million of working capital, and said it does not currently expect to need additional capital. Management is targeting profitability as it approaches Q1 2027.
• Reported loss per share was sharply affected by a financing-related accounting item: A non-cash $4.5 million deemed dividend tied to an August warrant inducement brought Q3 net loss available to common stockholders to $5.9 million, or $4 per share, despite improvement in the operating loss. Hardware revenue also fell to $12,000 from $364,000 a year earlier, with a large customer order delayed into smaller shipments.

BIO-key International Price Performance

NASDAQ BKYI traded down $0.46 during trading hours on Friday, hitting $2.12. The company had a trading volume of 215,583 shares, compared to its average volume of 1,709,838. The firm’s 50 day moving average is $2.47 and its 200 day moving average is $4.41. BIO-key International has a fifty-two week low of $1.55 and a fifty-two week high of $10.70. The company has a market capitalization of $4.32 million, a price-to-earnings ratio of -0.52 and a beta of 0.52.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on BKYI shares. Zacks Research raised BIO-key International to a “hold” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of BIO-key International in a research report on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of BIO-key International to a “hold” rating in a report on Saturday, October 24th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BIO-key International currently has an average rating of “Reduce”.

BIO-key International Company Profile

BIO-key International, Inc. (NASDAQ: BKYI) develops biometric authentication and identity and access management solutions. The company helps organizations secure access to applications, networks, devices and data through fingerprint recognition and other authentication methods designed to reduce reliance on passwords. Its product portfolio includes PortalGuard, an identity and access management platform that supports single sign-on, multifactor authentication, self-service password management and access control.